Immune Design Corp., a clinical-stage immunotherapy company, engages in the research and development of in vivo treatments for cancer. The company primarily develops oncology product candidates based on its ZVex and GLAAS discovery platforms. Its lead products include CMB305, a cancer vaccine targeting the NY-ESO-1 tumor antigen, which is in Phase 2 trial for the treatment of patients with synovial and MRCL sarcoma as a monotherapy; and G100, an antigen agnostic intratumoral product candidate as a monotherapy and combination therapy for the treatment of patients with follicular non-Hodgkin Lymphoma. The company is also developing CA21, a multi-targeting prime boost for the treatment of multiple solid tumors; and ZVex-IL12 for the treatment of TBD tumors. In addition, its technologies are used in the fields of infectious and allergic diseases. The company has license agreements with California Institute of Technology, University of North Carolina at Chapel Hill, TheraVectys SA, Infectious Disease Research Institute, MedImmune LLC, and Sanofi; and a collaboration agreement with Sanofi Pasteur. Immune Design Corp. was founded in 2008 and is headquartered in Seattle, Washington.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:IMDZ
Previous Symbol
CUSIPN/A
Phone206-682-0645
Debt
Debt-to-Equity RatioN/A
Current Ratio13.11
Quick Ratio12.95
Price-To-Earnings
Trailing P/E Ratio-1.15
Forward P/E Ratio-1.76
P/E GrowthN/A
Sales & Book Value
Annual Sales$7.20 million
Price / Sales13.45
Cash FlowN/A
Price / Cash FlowN/A
Book Value$2.90 per share
Price / Book0.69
Profitability
EPS (Most Recent Fiscal Year)($1.75)
Net Income$-51,860,000.00
Net Margins-2,409.84%
Return on Equity-43.44%
Return on Assets-40.33%
Miscellaneous
Employees56
Outstanding Shares48,170,000
Market Cap$96.81 million
OptionableOptionable
Immune Design (NASDAQ:IMDZ) Frequently Asked Questions
What is Immune Design's stock symbol?
Immune Design trades on the NASDAQ under the ticker symbol "IMDZ."
How were Immune Design's earnings last quarter?
Immune Design Corp (NASDAQ:IMDZ) issued its quarterly earnings data on Tuesday, November, 6th. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.32) by $0.03. The biotechnology company earned $0.46 million during the quarter, compared to the consensus estimate of $0.75 million. Immune Design had a negative return on equity of 43.44% and a negative net margin of 2,409.84%. View Immune Design's Earnings History.
When is Immune Design's next earnings date?
What price target have analysts set for IMDZ?
5 equities research analysts have issued 1-year price targets for Immune Design's stock. Their forecasts range from $8.00 to $11.00. On average, they anticipate Immune Design's share price to reach $9.00 in the next twelve months. This suggests a possible upside of 347.8% from the stock's current price. View Analyst Price Targets for Immune Design.
What is the consensus analysts' recommendation for Immune Design?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immune Design in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Immune Design.
What are Wall Street analysts saying about Immune Design stock?
Here are some recent quotes from research analysts about Immune Design stock:
- 1. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and $7.75 price target. Our valuation is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug’s potential commercial profile. We believe upside potential exists as the company explores additional tumor indications for G100, as well as potential Immune Design Corp. December 3, 2018 H.C. WAINWRIGHT & CO. EQUITY RESEARCH 2contribution from pipeline development." (12/3/2018)
- 2. According to Zacks Investment Research, "Immune Design’s primary candidate, G100 is being developed for merkel cell carcinoma, follicular non-Hodgkin Lymphoma and sarcoma. The company’s initial focus is to assess the efficacy of G100 combined with Merck’s Keytruda in relapsed refractory follicular lymphoma patients who have received three prior lines of systemic therapy. The company’s strategic agreements with companies like Sanofi, Roche and Merck is positive as itnot only validate its GLAAS platform but also provide the company with funds in the form of collaboration and license revenues. Although such collaborations boost its pipeline development, heavy dependence on other companies for revenue growth increases the company’s vulnerability. However, in October 2018, Immune Design discontinued CMB305 cancer vaccine program, following a review of its portfolio. Shares of the company underperformed the industry year to date." (11/30/2018)
Has Immune Design been receiving favorable news coverage?
Headlines about IMDZ stock have trended positive on Sunday, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Immune Design earned a media sentiment score of 2.3 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 3.0 out of 10, indicating that recent news coverage is unlikely to have an effect on the stock's share price in the near future.
Are investors shorting Immune Design?
Immune Design saw a decline in short interest during the month of October. As of October 31st, there was short interest totalling 432,714 shares, a decline of 35.2% from the October 15th total of 667,850 shares. Based on an average daily trading volume, of 1,040,680 shares, the short-interest ratio is presently 0.4 days. Currently, 1.5% of the company's shares are short sold. View Immune Design's Current Options Chain.
Who are some of Immune Design's key competitors?
Some companies that are related to Immune Design include Progenics Pharmaceuticals (PGNX), Kalvista Pharmaceuticals (KALV), Insys Therapeutics (INSY), ZEALAND PHARMA/S (ZEAL), MediciNova (MNOV), Evolus (EOLS), Clementia Pharmaceuticals (CMTA), American Brivision (Holding) (ABVC), resTORbio (TORC), Aclaris Therapeutics (ACRS), OptiNose (OPTN), Verastem (VSTM), Marker Therapeutics (MRKR), Keryx Biopharmaceuticals (KERX) and Stemline Therapeutics (STML).
Who are Immune Design's key executives?
Immune Design's management team includes the folowing people:
- Dr. Carlos V. Paya, CEO, Pres & Director (Age 59)
- Mr. Stephen R. Brady, Exec. VP of Strategy & Fin. (Age 48)
- Dr. Jan Henrik Ter Meulen, Chief Scientific Officer (Age 55)
- Mr. Christopher Whitmore CPA, VP of Fin. & Admin.
- Sylvia Wheeler, Investor Relations Officer
Who are Immune Design's major shareholders?
Immune Design's stock is owned by a variety of of institutional and retail investors. Top institutional investors include EcoR1 Capital LLC (4.65%), Dimensional Fund Advisors LP (1.37%), FMR LLC (0.97%), Bridgeway Capital Management Inc. (0.46%), Renaissance Technologies LLC (0.31%) and Nexthera Capital LP (0.09%). Company insiders that own Immune Design stock include Bvf Partners L P/Il, Carlos V Paya, Franklin M Berger, Leo Guthart, Lewis W Coleman, Meulen Jan Henrik Ter, Peter Svennilson, Sergey Yurasov, Stephen R Brady and Wayne Gombotz. View Institutional Ownership Trends for Immune Design.
Which institutional investors are selling Immune Design stock?
IMDZ stock was sold by a variety of institutional investors in the last quarter, including EcoR1 Capital LLC and FMR LLC. Company insiders that have sold Immune Design company stock in the last year include Bvf Partners L P/Il, Carlos V Paya, Meulen Jan Henrik Ter, Sergey Yurasov and Stephen R Brady. View Insider Buying and Selling for Immune Design.
Which institutional investors are buying Immune Design stock?
IMDZ stock was purchased by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Renaissance Technologies LLC, Bridgeway Capital Management Inc., Nexthera Capital LP and Marshall Wace LLP. Company insiders that have bought Immune Design stock in the last two years include Franklin M Berger, Leo Guthart, Lewis W Coleman and Peter Svennilson. View Insider Buying and Selling for Immune Design.
How do I buy shares of Immune Design?
Shares of IMDZ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Immune Design's stock price today?
One share of IMDZ stock can currently be purchased for approximately $2.01.
How big of a company is Immune Design?
Immune Design has a market capitalization of $96.81 million and generates $7.20 million in revenue each year. The biotechnology company earns $-51,860,000.00 in net income (profit) each year or ($1.75) on an earnings per share basis. Immune Design employs 56 workers across the globe.
What is Immune Design's official website?
How can I contact Immune Design?
Immune Design's mailing address is 1616 EASTLAKE AVENUE EAST SUITE 310, SEATTLE WA, 98102. The biotechnology company can be reached via phone at 206-682-0645 or via email at [email protected]
MarketBeat Community Rating for Immune Design (NASDAQ IMDZ)
MarketBeat's community ratings are surveys of what our community members think about Immune Design and other stocks. Vote "Outperform" if you believe IMDZ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMDZ will underperform the S&P 500 over the long term. You may vote once every thirty days.
